Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136589> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4324136589 endingPage "692" @default.
- W4324136589 startingPage "692" @default.
- W4324136589 abstract "692 Background: Sarcomatoid mRCC exhibits poor prognosis and limited response to vascular endothelial growth factor pathway inhibition. Therefore, we assessed the efficacy of ICI combination therapy in this patient population using data from contemporary trials. Methods: MEDLINE and EMBASE were searched to identify phase III randomized controlled trials (RCTs) comparing the efficacy of ICI combinations with sunitinib monotherapy in patients with sarcomatoid mRCC. Patient important outcomes of interest included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and complete response (CR). Precomputed hazard ratios (HR) with 95% confidence intervals (CI) for survival outcomes and binary outcome data for response rates (expressed as relative risk [RR] were meta-analyzed using a DerSimonian-Lairds random-effects method. Mixed treatment comparisons among different ICI combinations were made using a network-meta-analysis within the Bayesian framework. The surface under the cumulative ranking curves (SUCRA) were computed to assess the relative treatment rankings. Results: Six RCTs with a total of 618 patients were considered eligible for inclusion. ICI combination therapy was significantly associated with improved OS (HR: 0.56; 95% CI: 0.43-0.72) and PFS (HR: 0.50; 0.40-0.62), increased ORR (RR: 2.42; 1.92-3.06), and CR (RR: 4.23; 2.00-8.93) when compared to sunitinib in patients with sarcomatoid mRCC (Table). The results were consistent with Hartung-Knapp adjustment. Mixed treatment comparisons using current data revealed no statistically significant differences among different ICI combinations. However, the combination of nivolumab-ipilimumab was consistently ranked higher (rank 2 for OS, ORR, and CR) and may potentially be more efficacious than other counterparts. Conclusions: Current evidence suggests improved survival, delayed disease progression and increased response rates with the use of ICI combination therapy in patients with sarcomatoid mRCC. [Table: see text]" @default.
- W4324136589 created "2023-03-15" @default.
- W4324136589 creator A5005077627 @default.
- W4324136589 creator A5018306647 @default.
- W4324136589 creator A5030233600 @default.
- W4324136589 creator A5047378398 @default.
- W4324136589 creator A5058350855 @default.
- W4324136589 creator A5058650905 @default.
- W4324136589 creator A5067550666 @default.
- W4324136589 creator A5068639858 @default.
- W4324136589 creator A5074582149 @default.
- W4324136589 creator A5076962565 @default.
- W4324136589 date "2023-02-20" @default.
- W4324136589 modified "2023-09-23" @default.
- W4324136589 title "Efficacy of immune-checkpoint inhibitor (ICI) combination as a first-line (1L) therapy in metastatic renal cell carcinoma (mRCC) with sarcomatoid histology: A systematic review and meta-analysis." @default.
- W4324136589 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.692" @default.
- W4324136589 hasPublicationYear "2023" @default.
- W4324136589 type Work @default.
- W4324136589 citedByCount "0" @default.
- W4324136589 crossrefType "journal-article" @default.
- W4324136589 hasAuthorship W4324136589A5005077627 @default.
- W4324136589 hasAuthorship W4324136589A5018306647 @default.
- W4324136589 hasAuthorship W4324136589A5030233600 @default.
- W4324136589 hasAuthorship W4324136589A5047378398 @default.
- W4324136589 hasAuthorship W4324136589A5058350855 @default.
- W4324136589 hasAuthorship W4324136589A5058650905 @default.
- W4324136589 hasAuthorship W4324136589A5067550666 @default.
- W4324136589 hasAuthorship W4324136589A5068639858 @default.
- W4324136589 hasAuthorship W4324136589A5074582149 @default.
- W4324136589 hasAuthorship W4324136589A5076962565 @default.
- W4324136589 hasConcept C121608353 @default.
- W4324136589 hasConcept C126322002 @default.
- W4324136589 hasConcept C143998085 @default.
- W4324136589 hasConcept C207103383 @default.
- W4324136589 hasConcept C2776999253 @default.
- W4324136589 hasConcept C2777472916 @default.
- W4324136589 hasConcept C2777701055 @default.
- W4324136589 hasConcept C2779490328 @default.
- W4324136589 hasConcept C2780030458 @default.
- W4324136589 hasConcept C2780739268 @default.
- W4324136589 hasConcept C2908647359 @default.
- W4324136589 hasConcept C3019894029 @default.
- W4324136589 hasConcept C44249647 @default.
- W4324136589 hasConcept C71924100 @default.
- W4324136589 hasConcept C82789193 @default.
- W4324136589 hasConcept C95190672 @default.
- W4324136589 hasConcept C99454951 @default.
- W4324136589 hasConceptScore W4324136589C121608353 @default.
- W4324136589 hasConceptScore W4324136589C126322002 @default.
- W4324136589 hasConceptScore W4324136589C143998085 @default.
- W4324136589 hasConceptScore W4324136589C207103383 @default.
- W4324136589 hasConceptScore W4324136589C2776999253 @default.
- W4324136589 hasConceptScore W4324136589C2777472916 @default.
- W4324136589 hasConceptScore W4324136589C2777701055 @default.
- W4324136589 hasConceptScore W4324136589C2779490328 @default.
- W4324136589 hasConceptScore W4324136589C2780030458 @default.
- W4324136589 hasConceptScore W4324136589C2780739268 @default.
- W4324136589 hasConceptScore W4324136589C2908647359 @default.
- W4324136589 hasConceptScore W4324136589C3019894029 @default.
- W4324136589 hasConceptScore W4324136589C44249647 @default.
- W4324136589 hasConceptScore W4324136589C71924100 @default.
- W4324136589 hasConceptScore W4324136589C82789193 @default.
- W4324136589 hasConceptScore W4324136589C95190672 @default.
- W4324136589 hasConceptScore W4324136589C99454951 @default.
- W4324136589 hasIssue "6_suppl" @default.
- W4324136589 hasLocation W43241365891 @default.
- W4324136589 hasOpenAccess W4324136589 @default.
- W4324136589 hasPrimaryLocation W43241365891 @default.
- W4324136589 hasRelatedWork W2150001502 @default.
- W4324136589 hasRelatedWork W2788498597 @default.
- W4324136589 hasRelatedWork W2889691785 @default.
- W4324136589 hasRelatedWork W2936603379 @default.
- W4324136589 hasRelatedWork W2981065291 @default.
- W4324136589 hasRelatedWork W3134949580 @default.
- W4324136589 hasRelatedWork W3152520552 @default.
- W4324136589 hasRelatedWork W3176849231 @default.
- W4324136589 hasRelatedWork W4285598862 @default.
- W4324136589 hasRelatedWork W4362587156 @default.
- W4324136589 hasVolume "41" @default.
- W4324136589 isParatext "false" @default.
- W4324136589 isRetracted "false" @default.
- W4324136589 workType "article" @default.